Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 192

Results For "IMI"

4130 News Found

Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr
News | November 13, 2023

Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr

he company posted total income during Q2 FY24 at Rs. 12.86 crore


Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr
News | November 13, 2023

Glenmark Pharma reports Q2 FY24 loss at Rs. 62 Cr

European operations' revenue grew 58.4% to Rs 599.7 crore


GSK registers 5% revenue growth in Q2 FY24
News | November 10, 2023

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix


SMS Pharmaceuticals reports robust Q2FY24 operational performance
News | November 10, 2023

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore


Intermountain Health files complain against Dr. Reddy’s and others
News | November 10, 2023

Intermountain Health files complain against Dr. Reddy’s and others

Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation


Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
News | November 10, 2023

Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr

The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23


Lupin launches Rocuronium Bromide injection in US
Drug Approval | November 09, 2023

Lupin launches Rocuronium Bromide injection in US

Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).


Bayer posts Q3 2023 Group sales Euro 10.34 billion
News | November 09, 2023

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”


Biocon Biologics announces divestment of two non-core branded formulations
News | November 09, 2023

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million


Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
Drug Approval | November 08, 2023

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India